Cover of book: Medizinische Innovationen für Afrika
Buy in shop
, to see if you have full access to this publication.
Book Titles No access

Medizinische Innovationen für Afrika

Forschung und Produktentwicklung zur Bekämpfung vernachlässigter Krankheiten
Authors:
Publisher:
 2017

Bibliographic data

Copyright year
2017
ISBN-Print
978-3-8487-4311-7
ISBN-Online
978-3-8452-8581-8
Publisher
Nomos, Baden-Baden
Series
Studien des Büros für Technikfolgen-Abschätzung
Volume
44
Language
German
Pages
400
Product type
Book Titles

Table of contents

ChapterPages
  1. Titelei/Inhaltsverzeichnis No access 1 - 8
  2. Zusammenfassung No access 9 - 32
    1. Hintergrund No access
    2. Beauftragung, Zielsetzung und Vorgehensweise No access
    3. Kooperation mit Gutachtern No access
    4. Herausforderungen bei der Berichtserstellung und Aufbau des Berichts No access
      1. Gesundheit als Menschenrecht No access
      2. Erfassung von Gesundheitszuständen und -ungleichheiten No access
      1. Klassifikationen und Gruppierungen No access
      2. Indikatoren zu Verbreitung und Schwere von Krankheiten No access
      1. Globale Datensätze No access
      2. Befunde No access
      1. Medizinischer FuE-Bedarf No access
      2. Globaler Istzustand Forschung und Finanzierung No access
      3. Schätzungen zum Finanzbedarf No access
    5. Fazit No access
    1. Krankheitsverlauf Malaria – Wissen aus der Grundlagenforschung No access
      1. Prävention No access
      2. Diagnostik No access
      3. Therapie No access
    3. Operationelle Prozesse und Versorgung No access
    4. Globale Marktsegmente No access
    5. Fazit No access
    1. Normative Einordnung der Produktgruppen No access
      1. Grundlagenforschung No access
      2. Nachweis des Mechanismus No access
      3. Nachweis des Konzepts No access
      4. Nachweis der Wirksamkeit No access
      5. Integration neuer Produkte in die Versorgung No access
    3. Fazit und Schlussfolgerungen No access
      1. Relevante Schutzrechte am geistigen Eigentum No access
      2. Grundprinzipien, Geschäftsstrategien und Marktdynamiken No access
      3. Vernachlässigte Marktbereiche und gesundheits- bzw. wirtschaftspolitische Maßnahmen zur Gegensteuerung in Industrieländern No access
      4. Pro-und-Kontra-Debatte zum geistigen Eigentumsschutz No access
      1. Aktivitäten unter dem Dach der WIPO No access
      2. Aktivitäten unter dem Dach der WTO No access
      3. Europäische Freihandelsabkommen No access
      1. Sozialverträgliche Lizenzen No access
      2. Patentpools No access
      3. Medikamentenentwicklung durch Open Source oder Crowdsourcing? No access
    4. Fazit und Schlussfolgerungen No access
      1. Institutionelle FuE-Förderung No access
      2. Projektförderung No access
      3. Personelle Förderung No access
      4. Wirtschaftsförderung No access
      5. Förderung von Institutionen in Entwicklungs- und Schwellenländern No access
      6. Zusammenfassende Bewertung hinsichtlich PRND-FuE No access
      1. Forschungsrahmenprogramme No access
      2. European and Developing Countries Clinical Trials Partnership No access
      3. Zusammenfassende Bewertung hinsichtlich PRND-FuE No access
    3. Produktentwicklungspartnerschaften No access
      1. USA No access
      2. Großbritannien No access
      3. Zusammenfassender Ländervergleich No access
      1. Prämierungen von Forschungsergebnissen und Ideen No access
      2. Fonds zur Finanzierung von FuE im Gesundheitsbereich No access
    6. WHO: Analysen unterschiedlicher Instrumente No access
    7. Fazit und Schlussfolgerungen No access
    1. Methodisches Vorgehen No access
      1. Die deutsche FuE-Akteurslandschaft No access
      2. Nutzung öffentlicher Förderinstrumente No access
      3. PDP: Kooperationspartner auch für die Industrie No access
      4. Beteiligung südlicher Partner No access
      1. HIV/Aids No access
      2. Tuberkulose No access
      3. Malaria No access
      4. Protozoenkrankheiten (außer Malaria) No access
      5. Helminthosen No access
      6. Denguefieber, Lepra, Buruli-Ulkus sowie nichtspezifizierte vernachlässigte Krankheiten No access
      7. Aktivitäten nach Produktart No access
    4. Fazit und Schlussfolgerungen No access
  10. Resümee und Handlungsfelder No access 315 - 326
    1. In Auftrag gegebene Gutachten No access
    2. Weitere Literatur No access
    1. Vernachlässigte armutsassoziierte Krankheiten No access
    2. EU-Handelsabkommen mit Entwicklungs- und Schwellenländern (Stand Ende 2014) No access
    3. Produktentwicklungspartnerschaften No access
    4. Deutsche FuE-Einrichtungen mit PRND-Aktivitäten (2010 bis 2013) No access
    5. Deutsche Beteiligung an EDCTP-Projekten No access
    6. Abbildungen No access
    7. Kästen No access
    8. Tabellen No access
    9. Abkürzungen/Kurzglossar No access

Bibliography (390)

  1. In Auftrag gegebene Gutachten Open Google Scholar
  2. Eimer, T.R. (2012): Bittere Pillen oder faire Deals? Europäische Freihandelsabkom-men zwischen Innovationsschutz und Medikamentenversorgung. Berlin Open Google Scholar
  3. Edwards, S.; Mertenskötter, Th.; Glaue, F.; Meredith, St.; Meister, J. (2013): Medi-kamente für Afrika. Potenziale des Standorts Deutschland zur Bekämpfung von vernachlässigten Krankheiten. Berlin/Hamburg/Genf Open Google Scholar
  4. Rottenburg, R.; Beisel, U.; Jensen, N.; Park, S.-J. (2012): Medikamente für Afrika – Maßnahmen zur Verbesserung der gesundheitlichen Situation. Innovations- und Produktionsprozesse von Arzneimitteln – alternative Programme und Konzepte zur kommerzialisierten Forschung, Entwicklung und Produktion. Martin-Luther Universität Halle-Wittenberg, Halle Open Google Scholar
  5. Moldenhauer, O.; Frisch, Ph.; Gombe-Götz, S. (2012): »From Bench to Bedside«: Innovations- und Produktionsprozesse von Medizintools – alternative Konzepte zur Förderung von kommerzieller und nichtkommerzieller FuE, die einen breiten Zugang zu Innovationen sicherstellen. Berlin Open Google Scholar
  6. Weitere Literatur Open Google Scholar
  7. Abbott, R.B.; Bader, R.; Bajjali, L.; ElSamen, T.A.; Obeidat, Th.; Sboul, H.; Shwayat, M.; Alabbadi, I. (2012): The price of medicines in Jordan: the cost of trade-based intellectual property. In: Journal of Generic Medicines 9(2), S. 75–85 Open Google Scholar doi.org/10.1177/1741134312447499
  8. Abdulla, S.; Oberholzer, R.; Juma, O.; Kubhoja, S.; Machera, F.; Membi, C.; Omari, S.; Urassa, A.; Mshinda, H.; Jumanne, A.; Salim, N. et al. (2008): Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. In: New England Journal of Medicine 359(24), S. 2533–2544 Open Google Scholar doi.org/10.1056/NEJMoa0807773
  9. Adusei, P. (2011): Exploiting patent regulatory »Flexibilities« to promote access to antiretroviral medicines in Sub-Saharan Africa. In: The Journal of World Intellec-tual Property 14(1), S. 1–20 Open Google Scholar doi.org/10.1111/j.1747-1796.2010.00407.x
  10. Alonso, P.L.; Sacarlal, J.; Aponte, J.J.; Leach, A.; Macete, E.; Milman, J.,; Man-domando, I.; Spiessens, B.; Guinovart, C.; Espasa, M.; Bassat, Q. et al. (2004): Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. In: The Lan-cet, 364(9443), S. 1411–1420 Open Google Scholar
  11. AMF (Access to Medicine Foundation) (2013): Methodology Report 2013. www.accesstomedicineindex.org/sites/2015.atmindex.org/files/general/methodology_report_2013_for_the_2014_access_to_medicine_index.pdf (16.7.2015) Open Google Scholar
  12. AMF (2014): The Access to Medicine Index 2014. www.accesstomedicineindex.org/sites/2015.atmindex.org/files/2014_accesstomedicineindex_fullreport_clickablepdf.pdf (20.5.2015) Open Google Scholar
  13. Andersen, P.; Doherty, T.M. (2005): The success and failure of BCG – implications for a novel tuberculosis vaccine. In: Nat. Rev. Microbiol. 3(8), S. 656–662 Open Google Scholar doi.org/10.1038/nrmicro1211
  14. Aponte, J.J.; Aide, P.; Renom, M.; Mandomando, I.; Bassat, Q.; Sacarlal, J.; Manaca, M.N.; Lafuente, S.; Barbosa, A.; Leach, A; Lievens, M. et al. (2007): Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endem-ic area of Mozambique: a double blind randomised controlled phase I/IIb trial. In: Lancet 370(9598), S. 1543–1551 Open Google Scholar
  15. Armstrong Schellenberg, J.R.M.; Maokola, W.; Shirima, K.; Manzi, F.; Mrisho, M.; Mushi, A.; Alonso, P.; Mshinda, H.; Tanner, M.; Schellenberg, D.M. et al. (2011): Cluster-randomized study of intermittent preventive treatment for malar-ia in infants (IPTi) in southern Tanzania: evaluation of impact on survival. In: Malaria Journal 10:387 Open Google Scholar
  16. Asante, K.P.; Abdulla, S.; Agnandji, S.; Lyimo, J.; Vekemans, J.; Soulanoudjingar, S.; Owusu, R.; Shomari, M.; Leach, A.; Jongert, E.; Salim, N. et al. (2011): Safe-ty and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with ex-panded-programme-on-immunisation vaccines: 19 month follow-up of a random-ised, open-label, phase 2 trial. In: The Lancet infectious diseases 11, S. 741–749 Open Google Scholar doi.org/10.1016/S1473-3099(11)70100-1
  17. Barton, J.; Alexander, D.; Correa, C.M.; Mashelkar, R.; Samuels, G.; Thomas, S. (2002): Integrating intellectual property rights and development policy. Commis-sion on Intellectual Property Rights. London Open Google Scholar doi.org/10.1177/14680181020020030201
  18. Basheer, S. (2005): Indina's tryst with TRIPS: the patents (amendment) act, 2005. In: The Indian Journal of Law and Technology 1, S. 15–46 Open Google Scholar
  19. Beall, R.; Kuhn, R. (2012): Trends in compulsory licensing of pharmaceuticals since the Doha declaration: A database analysis. In: PLoS Medicine 9(1): e1001154 Open Google Scholar doi.org/10.1371/journal.pmed.1001154
  20. Bejon, P.; Lusingu, J.; Olotu, A.; Leach, A.; Lievens, M.; Vekemans, J.; Mshamu, S.; Lang, T.; Gould, J.; Dubois, M.-C.; Demoitié, M.-A. et al. (2008): Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. In: The New England Journal of Medicine 359(24), S. 2521–2532 Open Google Scholar doi.org/10.1056/NEJMoa0807381
  21. Belitz, H. (2013): Steuerliche Forschungsförderung ist ein stumpfes Schwert. www.diw. Open Google Scholar
  22. de/documents/publikationen/73/diw_01.c.430371.de/13-44-4.pdf (13.7.2015) Open Google Scholar
  23. Berninger, M. (2013): Max-Planck-Innovation – die Technologietransfer-Organisation der Max-Planck-Gesellschaft. www.mpg.de/6956260/MPI_JB_2013?c=7291695& Open Google Scholar
  24. force_lang=de (28.7.2015) Open Google Scholar
  25. BMBF (Bundesministerium für Bildung und Forschung) (2011): Förderkonzept Ver-nachlässigte und armutsassoziierte Krankheiten. www.bmbf.de/pub/vernachlaes- Open Google Scholar
  26. sigte_armutsassoziierte_krankheiten.pdf (9.1.2014) Open Google Scholar
  27. BMBF (2013): Roadmap für Forschungsinfrastrukturen. www.bmbf.de/pub/Roadmap. Open Google Scholar
  28. pdf (1.4.2015) Open Google Scholar
  29. BMBF (2014a): Die Afrika-Strategie 2014-2018. www.bmbf.de/pub/Afrika-Strategie_ Open Google Scholar
  30. 2014-2018.pdf (9.1.2014) Open Google Scholar
  31. BMBF (2014b): Bundesbericht Forschung und Innovation 2014. www.bmbf.de/pub/ Open Google Scholar
  32. BuFI_2014_barrierefrei.pdf (13.7.2015) Open Google Scholar
  33. BMBF (2015): Globale Gesundheit im Mittelpunkt der Forschung. Förderkonzept: Vernachlässigte und armutsassoziierte Krankheiten. www.bmbf.de/pub/Globale_ Open Google Scholar
  34. Gesundheit.pdf (20.11.2015) Open Google Scholar
  35. BMWi (Bundesministerium für Wirtschaft und Technologie) (2011): Exportinitiative Gesundheitswirtschaft. Berlin Open Google Scholar
  36. BMZ (Bundesministerium für wirtschaftliche Zusammenarbeit und Entwicklung) (2009): BMZ Spezial 162: Gesundheit und Menschenrechte. http://www.bmz.de/ Open Google Scholar
  37. de/mediathek/publikationen/archiv/reihen/strategiepapiere/spezial162.pdf Open Google Scholar
  38. (29.10.2014) Open Google Scholar
  39. BMZ (2015): BMZ baut Engagement im Gesundheitsbereich in Afrika aus. Presse-meldung vom 16.4., Berlin/Yaoundé, www.bmz.de/20150416-3 (1.12.2015) Open Google Scholar
  40. Boettiger, S. Burk, D.L. (2004): Open Source Patenting. In: Journal of International Biotechnology Law, 1, S. 221–231 Open Google Scholar doi.org/10.1515/jibl.2004.1.6.221
  41. Bojang, K.A.; Milligan, P.J.; Pinder, M.; Vigneron, L.; Alloueche, A.; Kester, K.E.; Open Google Scholar
  42. Ballou, W.R.; Conway, D.J,; Reece, W.H.; Gothard, P.; Yamuah, L. et al. (2001): Efficacy of RTS,S/AS02 malaria vaccine against plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. In: The Lancet 358(9297), S. 1927–1934 Open Google Scholar
  43. Boseley, S. (2010): How GlaxoSmithKline chief has changed the agenda for big pharma. https://www.theguardian.com/business/2010/jan/20/glaxosmithkline-andrew-witty-drugs-developing-world (15.6.2015) Open Google Scholar
  44. Boulton, I.; Meredith, St.; Mertenskoetter, Th.; Glaue, F. (2014): Evaluation of the Product Development Partnerships (PDP) funding activities. www.dlr.de/pt/ Open Google Scholar
  45. Portaldata/45/Resources/Dokumente/Leitfaden/Evaluation_of_the_Product_De Open Google Scholar
  46. velopment_Partnerships_funding_activities.pdf (1.7.2015) Open Google Scholar
  47. Bundesregierung (2008a): Bericht über die stärkere Verzahnung von Maßnahmen der Entwicklungszusammenarbeit mit dem Ansatz der Exportunterstützung für Er-neuerbare Energien. Deutscher Bundestag, Drucksache 16/10476, Berlin Open Google Scholar
  48. Bundesregierung (2008b): Antwort auf die kleine Anfrage, Verkauf der Patente auf den Tuberkulose-Impfstoff VPM 1002 durch die Vakzine Projekt Management GmbH, Deutscher Bundestag, Drucksache 16/11500, Berlin Open Google Scholar
  49. Bundesregierung (2010): Rahmenprogramm Gesundheitsforschung der Bundesregie-rung. Deutscher Bundestag, Drucksache 17/4243, Berlin Open Google Scholar
  50. Bundesregierung (2012): Globalisierung gestalten – Partnerschaften ausbauen – Ver-antwortung teilen. Deutscher Bundestag, Drucksache 17/8600, Berlin Open Google Scholar
  51. Bundesregierung (2014): Bundesbericht Forschung und Innovation 2014. Deutscher Bundestag, Drucksache 18/1510, Berlin Open Google Scholar
  52. Bundesregierung (2015): DART 2020. Antibiotika-Resistenzen bekämpfen zum Wohl von Mensch und Tier. http://www.bundesgesundheitsministerium.de/fileadmin/ Open Google Scholar
  53. Datei-en/Publikationen/Ministerium/Broschueren/BMG_DART_2020_Bericht_dt. Open Google Scholar
  54. pdf (15.6.2015) Open Google Scholar
  55. bvgh (BIO Venture for Global Health) (2012): Global Health Primer 2012 Snapshot. www.bvgh.org/LinkClick.aspx?fileticket=PzndmHX3BSU%3d&tabid=91 (9.10.2014) Open Google Scholar
  56. bvgh (2014): Global Health Primer. www.bvgh.org/Current-Programs/Neglected-Disease-Product-Pipelines/Global-Health-Primer.aspx (9.10.2014) Open Google Scholar
  57. Carruthers, B.G.; Ariovich, L. (2004): The sociology of property rights. In: Annual Review of Sociology 30, S. 23–46 Open Google Scholar doi.org/10.1146/annurev.soc.30.012703.110538
  58. Cartagena, R.G.; Attaran, A.( 2009): A study of pharmaceutical data exclusivity laws in Latin America: Is access to affordable medicine threatened? In: Health Law Journal 17, S. 269–296 Open Google Scholar
  59. CDER (Center for Drug Evaluation and Research, U.S. Department of Health and Human Services Food and Drug Administration) (2014): Guidance for industry neglected tropical diseases of the developing world: developing drugs for treat-ment or prevention. www.fda.gov/downloads/drugs/guidancecomplianceregulato Open Google Scholar
  60. ryinformation/guidances/ucm269221.pdf (7.8.2015) Open Google Scholar
  61. Centad (2009): Glaring disparities. In: Trading Up, 5(1), S. 25 Open Google Scholar
  62. CESCR (UN Committee on Economic, Social and Cultural Rights) (2000): General comment No. 14: The right to the highest attainable standard of health (Art. 12 of the Covenant) E/C.12/2000/4, www.refworld.org/docid/4538838d0.html (29.10.2014) Open Google Scholar
  63. CEWG (Consultative Expert Working Group on Research and Development: Financ-ing and Coordination) (2012a): Research and development to meet health needs in developing countries: Strengthening global financing and coordination. www.who. Open Google Scholar
  64. int/phi/CEWG_Report_5_April_2012.pdf (8.8.2014) Open Google Scholar
  65. CEWG (2012b): Defining Disease Types I, II and III. www.who.int/phi/3-back Open Google Scholar
  66. ground_cewg_agenda_item5_disease_types_final.pdf?ua=1 (8.8.2014) Open Google Scholar
  67. CGD (Center for Global Development) (2011): Safer, faster, cheaper. Improving clin-ical trials and regulatory pathways to fight neglected diseases. Report of the Center for Global Development's Working Group on Clinical Trials and Regula-tory Pathways. www.cgdev.org/files/1425588_file_Bollyky_Clinical_Trials_FINAL.pdf Open Google Scholar
  68. (10.5.2015) Open Google Scholar
  69. Chakraborty, S.; Singhvi, A. (2009): Patent reform and compulsory licensing: a case study from India. In: International Journal of Intellectual Property Management 3(2); S. 127–140 Open Google Scholar doi.org/10.1504/IJIPM.2009.023260
  70. Charité (2012): Drittmittelsatzung der Medizinischen Fakultät Charité – Universi-tätsmedizin Berlin. In: Amtliches Mitteilungsblatt Charité Universitätsmedizin Nr. 93 Open Google Scholar
  71. Charnovitz, S. (1998): Patent harmonization under world trade rules. In: The Journal of World Intellectual Property 1(1), S. 127–137 Open Google Scholar doi.org/10.1111/j.1747-1796.1998.tb00007.x
  72. Chirac, P.; Torreele, P. (2006): Global framework on essential health R&D. In: The Lancet 367, S. 1560-1561 Open Google Scholar doi.org/10.1016/S0140-6736(06)68672-8
  73. CIPIH (Commission on Intellectual Property Rights, Innovation and Public Health) (2006): Public Health – innovation and intellectual property rights. www.who.int/ Open Google Scholar
  74. intellectualproperty/documents/thereport/ENPublicHealthReport.pdf?ua=1 Open Google Scholar
  75. (30.6.2015) Open Google Scholar
  76. CIPR (Commission on Intellectual Property Rights) (2002): Integrating intellectual property rights and development policy. www.iprcommission.org/papers/pdfs/ Open Google Scholar
  77. final_report/CIPRfullfinal.pdf (15.6.2015) Open Google Scholar
  78. CMH (Commission on Macroeconomics and Health) (2001): Macroeconomics and health: investing in health for economic development. Genf Open Google Scholar
  79. Correa, C.M. (2006): Implications of bilateral free trade agreements on access to medicines. In: Bulletin of the World Health Organization 84(5), S. 399–404 Open Google Scholar doi.org/10.2471/BLT.05.023432
  80. Croft, A.M. (2007): A lesson learnt: the rise and fall of Lariam and Halfan. In: Jour-nal of the Royal Society of Medicine 100(4), S. 170–174 Open Google Scholar doi.org/10.1177/014107680710011411
  81. Cukier, K.N. (2003): Open source biotech: can a non-proprietary approach to intellec-tual property work in the life sciences? In: The Acumen Journal of Life Sciences 1(3), www.cukier.com/writings/opensourcebiotech.html (25.6.2015) Open Google Scholar
  82. Cullet, P. (2003): Patents and medicines: the relationship between TRIPS and the human right to health. In: International Affairs 79(1), S. 139–160 Open Google Scholar doi.org/10.1111/1468-2346.00299
  83. Cygnus (2005): Industry insight: indian pharmaceuticals. Cygnus Business Consult-ing & Research Pvt Ltd. Hyderabad Open Google Scholar
  84. Deere-Birkbeck, C.; Marchant, R. (2010): The technical assistance principles of the WIPO development agenda and their practical implementation. Issue Paper 28 Open Google Scholar doi.org/10.7215/IP_IP_20100423
  85. DFID (Department for International Development), UK aid (2011): Multilateral Aid Review. Ensuring maximum value for money for UK aid through multilateral or-ganisations. www.gov.uk/government/uploads/system/uploads/attachment_data/ Open Google Scholar
  86. file/67583/multilateral_aid_review.pdf (10.7.2015) Open Google Scholar
  87. DiMasi, J.A.; Hansen, R.W.; Grabowski, H.G. (2003): The price of innovation: new estimates of drug development costs. In: Journal of Health Economics 22(2), S. 151–185 Open Google Scholar doi.org/10.1016/S0167-6296(02)00126-1
  88. Dixit, N. (2008): A study of the role of government of India in helping indian phar-ma industry cope up with the challenges of the product patent regime. In: Euro-pean Journal of Economics, Finance and Administrative Sciences 13, S. 47–56 Open Google Scholar
  89. DNDi (Drugs on Neglected Diseases) (2007): ASAQ press pack. www.dndi.org/ Open Google Scholar
  90. images/stories/pdf_products/ASAQ/ASAQ_presspack_final_reduced.pdf Open Google Scholar
  91. (13.3.2015) Open Google Scholar
  92. Doherty, J.F.; Pinder, M.; Tornieporth, N.; Carton, C.; Vigneron, L. et al. (1999): A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in the Gambia. In: The American Journal of Tropical Medicine and Hygiene 61(6), S. 865–868 Open Google Scholar doi.org/10.4269/ajtmh.1999.61.865
  93. Doshi, P. (2014): US incentive scheme for neglected diseases: a good idea gone wrong? In: The BMJ 2014;349:g4665 Open Google Scholar doi.org/10.1136/bmj.g4665
  94. Daugla, D.M.; Gami, J.P.; Gamougam, K.; Naibei, N.; Mbainadji, L.; Narbé, M.; Toralta, J.; Kodbesse, B.; Ngadoua, C.; Coldiron, M.E.; Fermon, F. et al. (2014): Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. In: The Lancet 383(9911):40–7 Open Google Scholar doi.org/10.1016/S0140-6736(13)61612-8
  95. Drahos, P. (2001): BITs and BIPs. In: The Journal of World Intellectual Property, 4(6), S. 791–808 Open Google Scholar doi.org/10.1111/j.1747-1796.2001.tb00138.x
  96. Drahos, P. (2007): Trust me: patent offices in developing countries. Australian Na-tional University Working Paper 11 Open Google Scholar doi.org/10.2139/ssrn.1028676
  97. Drahos, P.; Braithwaite, J. (2002): Information feudalism. London Open Google Scholar
  98. Drahos, P.; Maher, I. (2004): Innovation, competition, standards and intellectual porperty: policy perspectives from economics and law. In: Information Econom-ics and Policy (16), S. 1–11 Open Google Scholar
  99. Dreyfuss, R. (2009): The role of India, China, Brazil and other emerging economies in establishing access norms for intellectual property and intellectual property lawmaking. Paper read at International Law and Justice Working Papers, New York Open Google Scholar doi.org/10.2139/ssrn.1442785
  100. DSW (Deutsche Stiftung Weltbevölkerung) (2014): EDCTP 2 auf einen Blick. www.letssavelives.org/wp-content/uploads/2014/10/1406_EDCTP-Deutch_A4_ Open Google Scholar
  101. web.pdf (10.7.2015) Open Google Scholar
  102. DZIF (Deutsches Zentrum für Infektionsforschung) (2013): Jahresbericht 2013. www.bmbf.de/pubRD/DZIF-JB13_barrierefrei_Final_Deutsch.pdf (3.7.2015) Open Google Scholar
  103. EC (European Commission) (2006): Global Europe Competing the World: European Commission, External Trade. http://trade.ec.europa.eu/doclib/docs/2006/october/ Open Google Scholar
  104. tradoc_130376.pdf (15.6.2015) Open Google Scholar
  105. EC (2010): Trade, Growth and World Affairs Trade Policy as a core component of the EU's 2020 strategy. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri= Open Google Scholar
  106. COM:2010:0612:FIN:EN:PDF (15.6.2015) Open Google Scholar
  107. EC (2012): Trade, growth and development Tailoring trade and investment policy for those countries most in need. http://trade.ec.europa.eu/doclib/docs/2012/january/ Open Google Scholar
  108. tradoc_148992.EN.pdf (15.6.2015) Open Google Scholar
  109. EC (2015): CETA – Zusammenfassung der abschließenden Verhandlungsergebnisse. http://trade.ec.europa.eu/doclib/docs/2015/february/tradoc_153081.pdf (9.6.2016) Open Google Scholar
  110. EDCTP (European and Developing Countries Clinical Trials Partnership) (2003): EDCTP policy on intellectual property rights. www.edctp.org/fileadmin/docu Open Google Scholar
  111. ments/EDCTP_Intellectual_Property_Rights_Policy.pdf (10.7.2015) Open Google Scholar
  112. EDCTP (2013): Annual report 2013. www.edctp.org/web/app/uploads/2014/12/ Open Google Scholar
  113. EDCTP_Annual_Report_2013_EN.pdf (2.7.2015) Open Google Scholar
  114. EDCTP (2014a): Scope of Phase II. www.edctp.org/calls-and-grants/scope/ (9.1.2014) Open Google Scholar
  115. EDCTP (2014b): Project portfolio. A compendium of clinical trials, capacity building and networking projects. www.edctp.org/fileadmin/documents/our_work/ Open Google Scholar
  116. EDCTP_project_portfolio.pdf (2.7.2015) Open Google Scholar
  117. EDCTP (2015): Funding prevention and treatment of HIV/AIDS, tuberculosis, ma-laria and neglected infectious diseases in places that need it most. www.edctp.org/ Open Google Scholar
  118. web/app/uploads/2015/05/EDCTP-corporate-folder-2015.pdf (2.7.2015) Open Google Scholar
  119. EFI (Expertenkommission Forschung und Innovation) (2014): Gutachten zur For-schung, Innovation und technologischer Leistungsfähigkeit Deutschlands 2014. www.e-fi.de/fileadmin/Gutachten_2014/EFI_Gutachten_2014.pdf (13.7.2015) Open Google Scholar
  120. EFI (2015): Gutachten zur Forschung, Innovation und technologischer Leistungsfä-higkeit Deutschlands 2015. www.e-fi.de/fileadmin/Gutachten_2015/EFI_Gutachten_ Open Google Scholar
  121. 2015.pdf (13.7.2015) Open Google Scholar
  122. EFPIA (European Federation of Pharmaceutical Industries and Associations) (2010): Public Consultation on a Future EU External Trade Policy. EFPIA Comments, S. 1–9 Open Google Scholar
  123. Ehlkes, L.; Kreuels, B.; Schwarz, N.G.; May, J. (2015): Epidemiologie des Ebolafie-bers und anderer, in Deutschland seltener hochkontragiöser, lebensbedrohlicher Erkrankungen. In: Bundesgesundheitsblatt 58, S. 705–713 Open Google Scholar doi.org/10.1007/s00103-015-2165-y
  124. Eimer, T.R.; Lütz, S. (2010): Developmental states, civil society, and public health: Patent regulation for HIV/AIDS pharmaceuticals in India and Brazil. In: Regula-tion and Governance 4(2), S. 135–153 Open Google Scholar doi.org/10.1111/j.1748-5991.2010.01074.x
  125. Eimer, T.R.; Philipps, A. (2011): Networks hanging loose: The domestic sources of US-EU patent disputes. In: Review of International Political Economy, 18(4), S. 460–480 Open Google Scholar doi.org/10.1080/09692291003600383
  126. Eimer, T.R.; Schüren, V. (2013): Convenient stalemates: Why international patent law negotiations continue despite deadlock. In: New Political Economy 18(4), S. 533–554 Open Google Scholar doi.org/10.1080/13563467.2013.742882
  127. Engel, J. (2002): Miltefosine, the story of a successful partnership: disease endemic country – TDR – pharmaceutical industry (Zentaris). In: TDR-News 68, S. 5 Open Google Scholar
  128. EWG (Expert Working Group on R&D financing and coordination) (2010): Research and development. Coordination and financing. www.who.int/phi/documents/ Open Google Scholar
  129. RDFinancingEN.pdf (10.12.2015) Open Google Scholar
  130. Fidock, D.A.; Nomura, T.; Talley, A.K.; Cooper, R.A.; Dzekunov, S.M.; Ferdig, M.T.; Ursos, L.M.B.; Sidhu, A.S.; Naudé, B.; Deitsch, K.W.; Su, X. et al. (2000): Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. In: Molecular Cell 6(4), S. 861–871 Open Google Scholar
  131. Frenz, W. (2011): Auswärtiges Handeln der Union. In: Handbuch Europarecht, Ber-lin/Heidelberg Open Google Scholar doi.org/10.1007/978-3-540-31101-0_36
  132. GAO (United States Feneral Accounting Office) (1998): Technology transfer admin-istration of the Bayh-Dole Act by Research Universities. www.gao.gov/archive/ Open Google Scholar
  133. 1998/rc98126.pdf (7.8.2015) Open Google Scholar
  134. Gardner, M.J.; Hall, N.; Fung, E.; White, O.; Berriman, M.; Hyman, R.W.; Carlton, J.M.; Pain, A.; Nelson, K.E.; Bowman, S.; Paulsen, I.T. et al. (2002): Genome sequence of the human malaria parasite Plasmodium falciparum. In: Nature 419, S. 498–511 Open Google Scholar doi.org/10.1038/nature01097
  135. GAVI Alliance (2015): Advance market commitment for pneumococcal vaccines. Annual report. www.gavi.org/library/documents/amc/2015-pneumococcal-amc-annual-report/ (7.8.2015) Open Google Scholar
  136. George, J.; Sheshadri, R.; Grover, A. (2009): Intellectual property and access to med-icines: developments and civil society initiatives in India. In: Reis, R.; Terto Jr., V.; Pimenta, M.C. (Hg.): Intellectual property rights and access to ARV medi-cines: Civil Society Resistance in the global south. Rio de Janeiro, S. 110–136 Open Google Scholar
  137. Gerlinger, K. (2013): Neues TA-Projekt: Arzneimittelentwicklung für Entwicklungs-länder. In: TAB-Brief Nr. 42, S. 19–26 Open Google Scholar
  138. Gerlinger, K. (2014): Medikamentenentwicklung für Afrika: Projektgenese im Deut-schen Bundestag. In: TAB-Brief Nr. 43, S. 33–34 Open Google Scholar
  139. Ghaffar, A.; IJsselmuiden, C.; Zicker, F. (2008): Changing mindsets. Research capac-ity strengthening in low and middle-income countries. www.cohred.org/ Open Google Scholar
  140. downloads/cohred_publications/Changing_Mindsets.pdf (28.7.2015) Open Google Scholar
  141. Ghansah, A.; Amenga-Etego, L.; Amambua-Ngwa, A.; Andagalu, B.; Apinjoh, T.; Bouyou-Akotet, M.; Cornelius, V.; Golassa, L.; Andrianaranjaka, VH.; Ishen-goma, D.; Johnson, K. et al. (2014): Monitoring parasite diversity for malaria elimination in sub-Saharan Africa. In: Science 345(6202), S. 1297–1298 Open Google Scholar
  142. Godt, C. (2010): Equitable Licensing. Lizenzpolitik & Vertragsbausteine. med4all. Oldenburg. http://med4all.org/fileadmin/med/pdf/lizenz_med4all_final.pdf Open Google Scholar
  143. (15.6.2015) Open Google Scholar
  144. Gontijo, C. (2005): Die Veränderungen im Patentsystem – Von der Pariser Verband-sübereinkunft zum TRIPS-Abkommen – Die Position Brasiliens. FDCL, S. 79–100 Open Google Scholar
  145. Goulding, R.; Palriwala, A. (2012): Patent pools: assessing their value-added for global health innovation and access. Results for Development Institute. Wash-ington (D.C.), http://healthresearchpolicy.org/assessments/patent-pools-assessing- their-value-added-global-health-innovation-and-access 15.6.2015) Open Google Scholar
  146. Grace, C.; Druce, N. (2009): External review of product development partnership grant framework. www.mmv.org/sites/default/files/uploads/docs/publications/PDP_Eva Open Google Scholar
  147. luation_-_Final__25_Nov.pdf (15.7.2015) Open Google Scholar
  148. Grace, C.; Pearson, M.; Lazdins, J. (2011): Pooled funds: assessing new models for financing global health R&D. Technical Background Paper. Results for Devel-opment Institute. http://healthresearchpolicy.org/sites/healthresearchpolicy.org/files/ Open Google Scholar
  149. assess-ments/files/Pooled%20Funding%20Technical%20Background%20Paper.pdf (20.5.2015) Open Google Scholar
  150. Grosse Ruse-Khan, H. (2011): The international law relation between TRIPS and subsequent TRIPS-Plus free trade agreements: Towards safeguarding TRIPS flexibilities? In: Journal of Intellectual Property Law 18(2), S. 1–41 Open Google Scholar
  151. Grosse Ruse-Khan, H.; Jaeger, T.; Kordic, R. (2011): The role of atypical acts in EU external trade and intellectual property policy. In: The European Journal of In-ternational Law 21 (4), S. 901–939 Open Google Scholar
  152. GSK (GlaxoSmithKline Biologicals), MVI PATH (Malaria Vaccine Initiative) (2011): Fact sheet: RTS,S Malaria Vaccine Candidate. www.malariavaccine.org/files/ Open Google Scholar
  153. RTSSfactsheetFINAL30September2011.pdf (8.4.2015) Open Google Scholar
  154. GSK (2014):GSK reicht Zulassungsunterlagen für Malaria-Kandidat-Impfstoff RTS,S ein. Pressemeldung, www.glaxosmithkline.de/mediaRelation.do?articleID=presse- Open Google Scholar
  155. meldungen_e15201 (20.4.2015) Open Google Scholar
  156. Gurel, O. (2007): Abbott vs. Thailand has implications for innovation and access. http://wtnnews.com/articles/3886/ (15.6.2015) Open Google Scholar
  157. Guth, R.A. (2010): Glaxo tries a Linux approach. Drug maker shares its research data online in test of Open-source Principles. In. The Wall Street Journal vom 26.3.2010 Open Google Scholar
  158. Hammes, B. (2000): Malaria – Medizinische und pflegerische Aspekte. Fachweiter-bildung für Anästhesie- und Intensivpflege des Universitätsklinikums Heidel-berg. www.klinikum.uni-heidelberg.de/uploads/media/Malaria.pdf (1.2.2015) Open Google Scholar
  159. Hansell, G.; Kotzen, J.; Plaschke, F.; Olsen, E.; Farag, H. (2015): Value creation for the rest of us. The Boston Consulting Group, www.bcgperspectives.com/content/ Open Google Scholar doi.org/10.1002/9781119204084.ch31
  160. articles/value-creation-strategy-value-creators-report-2015/ (28.7.2015) Open Google Scholar
  161. Harnrieder, T.; Kreuder-Sonnen, Ch. (2014): Institutioneller Wandel durch Krisen. Ebola als Reformschub für die globale Gesundheitsarchitektur. In: WZB Mittei-lungen Nr. 146, S. 36–39 Open Google Scholar
  162. Head, M.G.; Fitchett, J.R.; Cooke, M.K.; Wurie, F.B.; Hayward, A.C.; Atun, R. (2012): UK investments in global infectious disease research 1997–2010: a case study. In: The Lancet Infectious Diseases 13(1), S. 55–64 Open Google Scholar
  163. Herrling, P.L. (2008): Making drugs accessible to poor populations: a funding model. In: Global Forum Update on Research for Health 5. www.who.int/phi/Novartis. Open Google Scholar
  164. pdf, (25.7.2015) Open Google Scholar
  165. Hestermeyer, H. (2007): Human rights and the WTO. The case of patents and access to medicine. Oxford Open Google Scholar
  166. Hestermeyer, H. (2012): Menschenrecht auf Gesundheit und Patentschutz– ein Wi-derspruch? Der Zugang zu unentbehrlichen Medikamenten in Entwicklungs- und Schwellenländern. Forum Bioethik. www.ethikrat.org/dateien/pdf/fb-21-11-2012-simultanmitschrift.pdf (5.1.2014) Open Google Scholar
  167. Hoekman, B.M.; Kostecki, M.M. (2001): The political economy of the world trading system. The WTO and beyond. Oxford Open Google Scholar doi.org/10.1093/019829431X.003.0016
  168. Holt, R.A.; Subramanian, G.M.; Halpern, A.; Sutton, G.G.; Charlab, R.; Nusskern, D.R.; Wincker, P.; Clark, AG.; Ribeiro, J.M.; Wides, R.; Salzberg, S.L. et al. (2002): The genome sequence of the Malaria mosquito Anopheles gambiae. In: Science DOI:10.1126/science.1076181, S. 129–149 Open Google Scholar doi.org/10.1126/science.1076181
  169. ICTSD (International Centre for Trade and Sustainable Development) (2005): Com-promise averts compulsory AIDS drug license in Brazil. www.iprsonline.org/ Open Google Scholar
  170. ictsd/docs/Comp_Licence_AIDS_Brazil_BRIDGES9-6-7-2.pdf (15.6.2015 Open Google Scholar
  171. IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) (2011): Data Exclusivity: Encouraging Development of New Medicines. www.ifpma.org/fileadmin/content/Publication/IFPMA_2011_Data_Exclusivity__En_Web.pdf (15.6.2015) Open Google Scholar
  172. IFPMA (2014): The pharmaceutical industry and global health. Facts and figures 2014. www.ifpma.org/fileadmin/content/Publication/2014/IFPMA_-_Facts_And_Figu Open Google Scholar
  173. res_2014.pdf (3.4.2015) Open Google Scholar
  174. IVCC (Innovative Vector Control Consortium) (2014): Annual Report 2013-14. www.ivcc.com/download/file/fid/527 (15.7.2015) Open Google Scholar
  175. Jaeger, T. (2010): The EU approach to IP protection in partnership agreements. In: Competition & Tax Law Research Paper. Max Planck Institute for Intellectual Property, München Open Google Scholar doi.org/10.2139/ssrn.1534483
  176. Jaenisch, T.; Sakuntabhai, A.; Wilder-Smith, A.; (2013): DengueTools. Dengue Re-search funded by the european commission-scientific strategies of three european Dengue Research Consortia. In: PLoS Neglected Tropical Diseases 7(12): e2320 Open Google Scholar
  177. Jamison, D.T.; Summers L.H.; Alleyne, G.; Arrow, K.J.; Berkley, S.; Binagwaho, A.; Bustreo, F.; Evans, D.; Feachern, R.G.A.; Frenk, J.; Ghosh, G. et al. (2013): Global health 2035: a world converging within a generation. In: The Lancet 382, S. 1898–1955 Open Google Scholar doi.org/10.1016/S0140-6736(13)62105-4
  178. Kaltwasser, B. (2015): Investoren mit lockeren Händen und tiefen Taschen. In: Tran-script 7/8, S. 8–11 Open Google Scholar
  179. Kappe, S.H.I.; Vaughan, A.M.; Boddey, J.A.; Cowman, A.F. (2010): That was then but this is now: Malaria research in the time of an eradication agenda. In: Science 328(5980), S. 862–866 Open Google Scholar
  180. Karunamoorthi, K. (2014): The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence. In: Malaria Journal 13:209 Open Google Scholar doi.org/10.1186/1475-2875-13-209
  181. Kayentao, K.;, Garner, P.; van Eijk, A.M.; Naidoo, I.; Roper, C.; Mulokozi, A.; MacArthur, J.R.; Luntamo, M.; Ashorn, P.; Doumbo, O.K.; ter Kuile, F.O. (2013): Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Af-rica: systematic review and meta-analysis. In: Journal of the American Medical Association 309(6), S. 594–604 Open Google Scholar doi.org/10.1001/jama.2012.216231
  182. King, C.H.; Bertino, A.M. (2008): Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. In: PLoS Neglected Tropical Diseases 2(3): e209 Open Google Scholar doi.org/10.1371/journal.pntd.0000209
  183. KoWi (Kooperationsstelle EU der Wissenschaftsorganisationen) (2014): Factsheet zu Open Access. www.kowi.de/Portaldata/2/Resources/horizon2020/KoWi-Fact Open Google Scholar
  184. sheet-Open-Access.pdf (20.7.2015) Open Google Scholar
  185. Krattiger, A.; Mahoney, R.T.; Chiluwal, A.; Kowalski, S.P. (2012): Patent infor-mation, freedom to operate and »Global Access«: A case study of Dengue vac-cines under development. Global Challenges Report, WIPO, www.wipo.int/export/sites/ Open Google Scholar
  186. www/policy/en/global_health/pdf/dengue.pdf (20.7.2015) Open Google Scholar
  187. Lacaze, C.; Kauss, T.; Kiechel, J.R.; Caminiti, A.; Fawaz, F.; Terrassin, L.; Cuart, S.; Grislain, L.; Navaratnam, V.; Ghezzoul, B.; Gaudin, K. et al. (2011): The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership. In: Malaraia Journal 10:142 Open Google Scholar doi.org/10.1186/1475-2875-10-142
  188. Laforgia, F.; Montobbio, F.; Orsenigo, L. (2009): IPRs and technological develop-ment in pharmaceuticals. Who is patenting what in Brazil after TRIPS? http://policy Open Google Scholar
  189. dialogue.org/files/events/LaForgia_Montobbio_Orsenigo_Who_is_Patenting_ Open Google Scholar
  190. What_in_Brazil.pdf (20.5.2015) Open Google Scholar
  191. Lansang, M.A.; Dennis, R. (2004): Building capacity in health research in the devel-oping world. In: Bulletin of the World Health Organization 82(10), S. 764–770 Open Google Scholar
  192. Le Bas, Ch. (2002): Foncitonnement, transformation et tensions du système de bre-vet. les implications du »Cours pro-brevet« à la lumière des études empiriques ré-centes. In: Revue d'é-conomie industrielle 99(2), S. 249–265 Open Google Scholar
  193. Leimer, R. (1979): Therapie und Prophylaxe der Malaria mit FANSIDAR. In: Mittei-lungen der Österreichischen Gesellschaft für Tropenmedizin und Parasitologie 1, S. 3–4 Open Google Scholar
  194. Lezaun, J.; Montgomery, C.M. (2015): The pharmaceutical commons: Sharing and exclusion in global health drug development. In: Science, Technology & Human Values 40(1), S. 3–29 Open Google Scholar doi.org/10.1177/0162243914542349
  195. Liebig, K. (2006): Auswirkungen des internationalen Patentregimes auf die Medika-mentenproduktion und den Zugang zu Medikamenten in LDC's. Studies Deut-sches Institut für Entwicklungspolitik 18, Bonn Open Google Scholar
  196. Light, D.W.; Warburton, R. (2011): Demythologizing the high costs of pharmaceuti-cal research. In: BioSocieties 6(1), S. 34–50 Open Google Scholar doi.org/10.1057/biosoc.2010.40
  197. Loucq, C. (2009): The RTS,S/AS malaria vaccine candidate. www.who.int/immuni Open Google Scholar
  198. zation/sage/20091028_MVI_SAGE_LOUCQ_FinalDraft.pdf (17.4.2015) Open Google Scholar
  199. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; Alvarado, M.; et al. (2012): Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. In: The Lan-cet 380, S. 2095–2128 Open Google Scholar doi.org/10.1016/S0140-6736(12)61728-0
  200. Marusak Hermann, R. (2011): WIPO Re: Search bridges public, private sectors for neglected disease research. Intellectual property watch, www.ip-watch.org/'2011/10/ Open Google Scholar
  201. 27/wipo-research-bridges-public-private-sectors-for-neglected-disease-research/ (15.06.2015) Open Google Scholar
  202. Masum, H.; Harris, R. (2011): Open source for neglected diseases. Magic bullet or mirage? Results for Development Institute. Washington (D.C.), http://healthresearch Open Google Scholar
  203. policy.org/sites/healthresearchpolicy.org/files/assessments/files/Open%20source Open Google Scholar
  204. %20high%20res.pdf (26.7.2015) Open Google Scholar
  205. Matthews, D.; Munoz-Tellez, V. (2006): Bilateral technical assistance and TRIPS: The United States, Japan and the European Communities in comparative pespec-tive. In: The Jour Journal of World Intellectual Property 9(6), S. 629–653 Open Google Scholar doi.org/10.1111/j.1422-2213.2006.00305.x
  206. Maurer, S.M.; Rai, A.; Sali, A. (2004): Finding cures for tropical diseases: is pen source an answer? In: PLoS Med 1(3): e56. https://doi.org/10.1371/journal.pmed.0010056 (25.6.2015) Open Google Scholar doi.org/10.1371/journal.pmed.0010056
  207. May, Ch. (2000): A global political economy of intellectual property rights. The new enclosures? London/New York Open Google Scholar
  208. McGready, R. (2009): Intermittent preventive treatment of Malaria in infancy. In: Lancet 9700(374), S. 1478–80 Open Google Scholar doi.org/10.1016/S0140-6736(09)61629-9
  209. Mischnik, A.; Klein, S.; Tintelnot, K.; Zimmermann, S.; Rickerts, V. (2013): Krypto-kokkose: Kasuistiken, Epidemiologie und Therapiestrategien. In: Deutsche Medizinische Wochenschrift 138 (30), S. 1533–1538 Open Google Scholar
  210. Moorthy, V.; Bosman, A. (2016): Update from WHO on RTS,S/AS01. Malaria Poli-cy Advisory Committee Meeting, 14.–16.9., WHO, Genf, http://apps.who.int/ma Open Google Scholar
  211. laria/mpac/mpac-sep2016-rtss-vaccine.pdf Open Google Scholar
  212. Moran, M. (2014): WHO plans for neglected diseases are wrong. In: Nature 506, S. 267 Open Google Scholar doi.org/10.1038/506267a
  213. Moran, M.; Ropars, A.L.; Guzman, J.; Diaz, J.; Garrison, C. (2005): The new land-scape of neclected disease drug development. www.policycures.org/downloads/The_ Open Google Scholar
  214. new_landscape_of_neglected_disease_drug_development.pdf (20.7.2015) Open Google Scholar
  215. Moran, M.; Guzman, J.; Henderson, K.; Liyanage, R.; Wu, L.; Chin, E.; Chapman, N.; Abela-Oversteegen, L.; Gouglas, D.; Kwong, D. (2012): Neglected disease research and development: A five year review. www.policycures.org/downloads/GF2012_ Open Google Scholar
  216. Report.pdf (9.1.2015) Open Google Scholar
  217. Moran, M.; Guzman, J.; Chapman, N.; Abela-Oversteegen, L.; Howard, R.; Farrell, P.; Luxford, J. (2013): Neglected disease research and development. The public divide. www.policycures.org/downloads/GF_report13_all_web.pdf (9.1.2015) Open Google Scholar
  218. Moran, M.; Guzman, J.; Chapman, N.; Abela-Oversteegen, L.; Whittall, C.; Howard, R.; Farrell, P.; Halliday, D.; Hirst, C. (2014): Neglected disease research and de-velopment. Emerging trends. www.policycures.org/downloads/Y7 %20GFINDER%20 Open Google Scholar
  219. full%20report%20web%20.pdf (9.1.2015) Open Google Scholar
  220. Morin, J.F.; Gold, E.R. (2010): Consensus-seeking, distrust and rhetorical entrap-ment: The WTO decision on access to medicines. In: European Journal of Inter-national Relations 16, S. 563–587 Open Google Scholar doi.org/10.1177/1354066110366054
  221. MSD (Merck Sharp & Dohme AG) (2012): 25 Jahre gegen Flussblindheit. www.msd.ch/German/news-room/Documents/MSD_MECTIZAN_Factsheet_ Open Google Scholar
  222. German_online_Switzerland.pdf (17.11.2014) Open Google Scholar
  223. MSF (Medecins Sans Frontiertes/Ärzte ohne Grenzen e.V.) (2008): Update 2011: Forschungszwerg Deutschland. www.aerzte-ohne-grenzen.de/sites/germany/files/at Open Google Scholar
  224. tachments/aerzte-ohne-grenzen-forschungszwerg-deutschland-2011.pdf (6.1.2016) Open Google Scholar
  225. MSF (2011): Update 2011: Forschungszwerg Deutschland. www.kleinteilige-loesungen. Open Google Scholar
  226. de/pictures_2011/forschungszwerg/update2011_forschungszwerg.pdf (2.2.2015) Open Google Scholar
  227. MSF (2014): Untangling the Web of antiretroviral price reductions, 17th edition. www. Open Google Scholar
  228. msfaccess.org/sites/default/files/MSF_UTW_17th_Edition_4_b.pdf (15.6.2015) Open Google Scholar
  229. MSF, BUKO Pharma-Kampagne, Evangelischer Entwicklungsdienst, Universities Allied for Essential Medicines Germany (Hg.) (2011): Forschung für vernachläs-sigte Krankheiten. Plädoyer für eine nachhaltige öffentliche Förderung. www.bukophar Open Google Scholar
  230. ma.de/uploads/file/Pharma-Brief/2011_02_spezial_Forschung.pdf (30.4.2015) Open Google Scholar
  231. Munos, B. (2006): Can open-source R&D reinvigorate drug research? In: Nature Re-views Drug Discovery 5, S. 723–729 Open Google Scholar
  232. Murray, C.J.L.; Ezzati, M.; Flaxman, A.D.; Lim, S.; Lozano, R.; Michaud, C.; Naghavi, M.; Salomon, J.A.; Shibuya, K.; Vos, T.; Wikler, D.; Lopez, A.D. (2012a): The Global Burden of Disease Study (2010): Design, definitions, and metrics. In: Lancet 380, S. 2063–2066 Open Google Scholar
  233. Murray, C.; Lopez, A.; Lozano, R.; Flaxman, A.; Vos, T.; Ezzati, M.; Whiteford, H.; Shibuya, K.; Michaud, C.; Cohen, A.; da Silva, J.B. (2012b): The story of GBD 2010: a »super-human« effort. In: The Lancet 380, S. 2067–2070 Open Google Scholar
  234. Murray, C.; Vos, T.; Lozano, R.; Naghavi, M.; Flaxman, A.D.; Michaud, C.; Ezzati, M.; Shibuya, K.; Salomon, J.A.; Abdalla, S.; Aboyans, V. et al. (2012c): Disabil-ity-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. In: The Lancet 380, S. 2197–2223 Open Google Scholar
  235. Musungu, S.F.; Oh, C. (2006): The use of flexibilities in TRIPS by developing coun-tries: can they promote access to medicines? www.who.int/entity/intellectualproperty/ Open Google Scholar
  236. studies/TRIPSFLEXI.pdf?ua=1 (15.6.2015) Open Google Scholar
  237. Neafsey, D.E.; Juraska, M.; Bedford., T.; Benkeser, D.; Valim, C.; Griggs, A.; Lie-vens, M.; Abdulla, S.; Adjei, S.; Agbenyega, T.; Agnandji, S.T. et al. (2015): Genetic diversity and protective efficacy of the RTS,S/AS01 Malaria vaccine. In: The New England Journal of Medicine, DOI: 10.1056/NEJMoa1505819 Open Google Scholar doi.org/10.1056/NEJMoa1505819
  238. North, D.C.; Thomas, R.P. (1973): The rise of the Western World. A New Economic History. Cambridge Open Google Scholar doi.org/10.1017/CBO9780511819438
  239. Novartis (2012): Geschäftsbericht 2012. www.novartis.com/downloads/investors/re Open Google Scholar
  240. ports/novartis-annual-report-2012-de.pdf (13.3.2015) Open Google Scholar
  241. Oliveira, M.A.; Bermudez, J.A.Z.; Costa Chaves, G.; Velásquez, G. (2004): Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? In: Bulletin of the World Health Organization 28 (11), S. 815–821 Open Google Scholar
  242. Olotu, A.; Lusingu, J.; Leach, A.; Lievens, M.; Vekemans, J.; Msham, S.; Lang, T.; Gould, J.; Dubois, M.C.; Jongert, E.; Vansadia, P. et al. (2011): Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tan-zania: a randomised controlled trial. In: Lancet Infect Dis. 11(2), S. 102–109 Open Google Scholar doi.org/10.1016/S1473-3099(10)70262-0
  243. Peterson, K.; Pfitzer, M.; Herman, L.S.L.; Russell, P.; Zapol, D.; Stamp, M. (2007): Toward a new approach to Product Development Partnership (PDP) performance measurement. www.fsg.org/publications/toward-new-approach-product-develop Open Google Scholar
  244. ment-partnership-pdp-performance-measurement (20.7.2015) Open Google Scholar
  245. Pfleiderer, M.; Wichmann, O. (2015): Von der Zulassung von Impfstoffen zur Emp-fehlung durch die Ständige Impfkommission in Deutschland. In: Bun-desgesundheitsblatt Nr. 58, S. 263–273 Open Google Scholar
  246. PhRMA (Pharmaceutical Research and Manufacturers of America) (2014): 2015 pro-file Biopharmaceutical Research Industry. www.phrma.org/sites/default/files/pdf/ Open Google Scholar
  247. 2014_PhRMA_PROFILE.pdf (11.5.2016) Open Google Scholar
  248. Pogge, T. (2011): Die richtigen Anreize schaffen: Der Health Impact Fund. http://library.fes.de/pdf-files/iez/08545.pdf (6.11.2014) Open Google Scholar
  249. Policy Cures, G-Finder (2013): Deutschlands Rolle in der Forschung und Entwick-lung (FuE) zu vernachlässigten und armutsassoziierten Krankheiten. http://policycures. Open Google Scholar
  250. org/downloads/GF_GermanReport_German.pdf (6.1.2016) Open Google Scholar
  251. Pollet-Fort, A.; Alksnis, A. (2010): Implications of the Lisbon Treaty on EU External Trade Policy. Background Brief 2, http://aei.pitt.edu/33652/1/LisbonImpacton Open Google Scholar
  252. Trade-rev6Mar.pdf (15.6.2015) Open Google Scholar
  253. Rao, A. (2011): R&D Tax Credits – a tool to advance global health technologies? http://healthresearchpolicy.org/assessments/rd-tax-credits-tool-advance-global-health-technologies (7.8.2015) Open Google Scholar doi.org/10.5912/jcb484
  254. RBM (Roll Back Malaria-Partnership) (2008): Der Globale Malaria-Aktionsplan. www.rollbackmalaria.org/gmap/gmap.pdf (26.01.2015) Open Google Scholar
  255. Revermann, C.; Sauter, A. (2007): Biobanken als Ressource der Humanmedizin. Be-deutung, Nutzen, Rahmenbedingungen. Studien des Büros für Technikfolgen-Ab¬schätzung beim Deutschen Bundestag 23, Berlin Open Google Scholar doi.org/10.5771/9783845269870-1
  256. RKI (Robert Koch Institut) (2012): RKI-Ratgeber für Ärzte: Malaria. www.rki.de/DE/ Open Google Scholar
  257. Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Malaria.html#doc2392924body Open Google Scholar
  258. Text8 (6.3.2015) Open Google Scholar
  259. Roberts, P.A. (2004): Malaria Vaccine Initiative. Intellectual property rights and vac-cines in developing countries. www.who.int/intellectualproperty/events/en/Patri Open Google Scholar
  260. cia.Roberts.pdf (25.6.2015) Open Google Scholar
  261. Robertson, A.S.; Stefanakis, R.; Joseph, D.; Moree, M. (2012): The impact of the US priority review voucher on private-sector investment in global health research and development. In: PLoS Neglected Tropical Diseases 6(8): e1750 Open Google Scholar doi.org/10.1371/journal.pntd.0001750
  262. Robinson, D.; Gibson, C.R. (2011): Governing Knowledge: Discourses and Tactics of the European Union in Trade-Related Intellectual Property Negotiations. In: Antipode 43(5), S. 1883–1910 Open Google Scholar doi.org/10.1111/j.1467-8330.2010.00860.x
  263. Rudack, T.; Perilla, J.; Schulten, K. (2014): Die Geheimnisse des Lebens berechnen. In. Spektrum der Wissenschaft 11(14), S. 86–95 Open Google Scholar
  264. Sacarlal, J.; Aide, P.; Aponte, J.J.; Renom, M.; Leach, A.; Mandomando, I.; Lievens, M.; Bassat, Q.; Lafuente, S.; Macete, E.; Vekemans, J. et al. (2009): Long-term safety and efficacy of the RTS,S/AS02A Malaria vaccine in Mozambican chil-dren. In: The Journal of Infectious Diseases 200(3), S. 329–336 Open Google Scholar doi.org/10.1086/600119
  265. Salomon, J.A.; Vos, Th.; Hogan, D.R.; Gagnon, M.; Naghavi, M.; Mokdad, A.; Begum, N.; Shah, R.; Karyana, M.; Kosen, S.; Farje, M.R. et al. (2012): Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. In: Lancet 380, S. 2129–2143 Open Google Scholar doi.org/10.1016/S0140-6736(12)61680-8
  266. Sampath, P. (2005): Economic aspects of access to medicines after 2005: Product patent protection and emerging firm strategies in the Indian pharmaceutical in-dustry. United Nations University – Institute for New Technologies (UNU-INTECH) Open Google Scholar
  267. Sampath, P. (2006): India's product patent protection regime: less or more of »pills for the poor«? UNU-MERIT Working Paper No. 2006–019, Maastricht Open Google Scholar doi.org/10.1111/j.1422-2213.2006.00308.x
  268. Sauter, A.; Gerlinger, K. (2012): Der pharmakologisch verbesserte Mensch. Leis-tungssteigernde Mittel als gesellschaftliche Herausforderung. Studien des Büros für Technikfolgen-Abschätzung beim Deutschen Bundestag 34, Berlin Open Google Scholar doi.org/10.5771/9783845270227-222
  269. Schlitzer, M. (2010): Lebensrettende Prophylaxe und Therapie. In Pharmazeutische Zeitung, www.pharmazeutische-zeitung.de/?id=33154 (21.02.2015) Open Google Scholar
  270. Schmiedchen, F.; Spennemann, Ch. (2007): Intellectual Property Rights and Public Health. Federation of German Scientists (FGS) Policy Papers 1/2007 Open Google Scholar
  271. Schumpeter, J.A. (1950): Kapitalismus, Sozialismus und Demokratie. Leo Lehnen Verlag, München Open Google Scholar
  272. Seeberger, P.H. (2015): Impfen mit Zucker. In: Spektrum der Wissenschaft 8/15, S. 29–34 Open Google Scholar
  273. So, A.D.; Sampat, B.N.; Rai, A.K.; Cook-Deegan, R.; Reichman, J.H.; Weissman, R.; Kapczynski, A.. (2008): Is Bayh-Dole good for developing countries? Lessons from the US experience. In: PloS Biology 6(10): e262 Open Google Scholar doi.org/10.1371/journal.pbio.0060262
  274. Spengel, C.; Wiegard, W. (2011): Ökonomische Effekte einer steuerlichen For-schungsförderung in Deutschland. http://spengel.bwl.uni-mannheim.de/forschung/veroef Open Google Scholar
  275. fentlichungen/15394_bdi_fue_titel_5.pdf (13.7.2015) Open Google Scholar
  276. Stevens, P. (2004): Diseases of poverty and the 10/90 gap. www.who.int/intellectual Open Google Scholar
  277. property/submissions/InternationalPolicyNetwork.pdf (8.10.2014) Open Google Scholar
  278. Stop TB Partnership, WHO (2006): Global Plan to Stop TB 2006–2015. Geneva Open Google Scholar
  279. Stop TB Partnership, WHO (2010): Global Plan to Stop TB 2011–2015. Geneva Open Google Scholar
  280. Stoute, J.A.; Slaoui, M.; Heppner, D.G.; Momin, P.; Kester, K.E. et al. (1997): A prelimi¬nary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum Malaria. In: The New England Journal of Medicine 336, S. 86–91 Open Google Scholar doi.org/10.1056/NEJM199701093360202
  281. TAB (Büro für Technikfolgen-Abschätzung beim Deutschen Bundestag) (2010): Wettbewerbsfähigkeit der europäischen Wirtschaft im Hinblick auf die EU-Beihilfe¬politik – am Beispiel der Nanoelektronik (Autoren: Wydra, S.; Blümel, C.; Nusser, M.; Thielmann, A.; Lindner, R.; Mayr, C.). TAB-Arbeitsbericht Nr. 137, Berlin Open Google Scholar
  282. TAB (2013): Technischer Fortschritt im Gesundheitswesen: Quelle für Kostensteige-rungen oder Chance für Kostensenkungen? (Autoren: Bratan, T.; Wydra, S.) TAB-Arbeitsbericht Nr. 157, Berlin Open Google Scholar
  283. TAB (2015): Responsible Research and Innovation. (Autoren: Lindner, R.; Schröder, Th.; Goos, K.; Güth, S.; Som, O.). TAB-Hintergrundpapier Nr. 23, Berlin Open Google Scholar doi.org/10.5771/9783845272825-81
  284. Tabernero, P.; Fernández, F.M.; Green, M.; Guerin, P.J.; Newton, P.N. (2014): Mind the gaps – the epidemiology of poor-quality anti-malarials in the malarious world – analysis of the WorldWide Antimalarial Resistance Network database. In: Ma-laria Journal 13:139 Open Google Scholar doi.org/10.1186/1475-2875-13-139
  285. TAG (Treatment Aciton Group), Stop TB Partnership (2013): Tuberculosis research and development: 2013 report on Tuberculosis research fundung trends, 2005-2012. www.treatmentactiongroup.org/sites/g/files/g450272/f/201310/TAG_TB_ Open Google Scholar
  286. 2013_8.5.pdf (22.1.2015) Open Google Scholar
  287. technopolis (2014): Review of the product development partnerships fund 2011–2014. www.technopolis-group.com/wp-content/uploads/2014/11/141118_PDP_Re Open Google Scholar
  288. view_Technopolis_Group4.pdf (15.7.2015) Open Google Scholar
  289. The RTS,S Clinical Trials Partnership (2011): First results of phase 3 trial of RTS,S/AS01 Malaria vaccine in African children. In: New England Journal of Medicine 365, S. 1863–1875 Open Google Scholar
  290. The RTS,S Clinical Trials Partnership (2014): Efficacy and safety of the RTS,S/AS01 Malaria vaccine during 18 months after vaccination: A phase 3 randomized, con-trolled trial in children and young infants at 11 African sites. In: PLoS Medicine 11(7): e1001685 Open Google Scholar
  291. The RTS,S Clinical Trials Partnership (2015): Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. In: Lancet 386, S. 31–45 Open Google Scholar
  292. t'Hoen, E.F.M. (2009): The global politics of pharmaceuctical monopoly power. Die-men: AMB Publishers Open Google Scholar
  293. t'Hoen, E.F.M.; Passarelli, C.A. (2013): The role of intellectual property rights in treatment access. In: Current Opinion in HIV and AIDS 8 (1), S. 70–74 Open Google Scholar doi.org/10.1097/COH.0b013e32835b6e5a
  294. UN (United Nations) (2006): World population prospects: The 2006 revision. www.un.org/esa/population/publications/wpp2006/WPP2006_Highlights_rev.pdf (26.1.2015) Open Google Scholar
  295. UNAIDS (2010): Getting to zero: 2011–2015 UNAIDS strategy. www.unaids.org/sites/ Open Google Scholar
  296. default/files/en/media/unaids/contentassets/documents/unaidspublication/2010/ Open Google Scholar
  297. JC2034_UNAIDS_Strategy_en.pdf (20.10.2014) Open Google Scholar
  298. UNAIDS (2014): GAP Report 2014. www.unaids.org/en/media/unaids/contentassets/ Open Google Scholar
  299. documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf (20.10.2014) Open Google Scholar
  300. UNAIDS, WHO, UNDP (2011): Using TRIPS flexibilities to improve access to HIV treatment. UNAIDS, WHO and UNDP POLICY BRIEF. www.unaids.org/sites/ Open Google Scholar
  301. default/files/media_asset/JC2049_PolicyBrief_TRIPS_en_1.pdf (15.6.2015) Open Google Scholar
  302. UNCTAD (United Nations Conference on Trade and Development) (2005): Re-source Book on TRIPS and Development. Cambridge Open Google Scholar
  303. UNEP (United Nations Environment Programme) (2007): Report of the expert group on the assessment of the production and use of DDT and its alternatives for dis-ease vector control. UNEP/POPS/COP.3/24 Open Google Scholar
  304. UNICEF (United Nations Children's Fund) (2011): Long lasting insecticidal nets price transparency. www.unicef.org/chinese/supply/files/Long_Lasting_Insecticidal_ Open Google Scholar
  305. Nets_Price_Transparency.pdf (20.3.2015) Open Google Scholar
  306. UNICEF; WHO (2013): Ending preventable child deaths from pneumonia and diar-rhoea by 2025. The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD). http://apps.who.int/iris/bitstream/10665/79200/1/9789241505239_eng. Open Google Scholar
  307. pdf (15.6.2015) Open Google Scholar
  308. USAID (2010): LLIN Market and data analysis. cost effectiveness study – Final report. http://deliver.jsi.com/dlvr_content/resources/allpubs/guidelines/LLINMarkData. Open Google Scholar
  309. pdf (20.3.2015) Open Google Scholar
  310. Usrey, K.B. (1999): The new information age and international intellectual property law – emerging and recurring issues for the next Millennium. In: Accounting Fo-rum 23 (4); S. 378–407 Open Google Scholar doi.org/10.1111/1467-6303.00022
  311. Vach, W.; Gerke, O. (2015): Nutzenbewertung diagnostischer Maßnahmen – quo vadismus? In: Bundesgesundheitsblatt Nr. 58, S. 256–262 Open Google Scholar
  312. van Benthem, J.B. (1990): Europäisches Patentsystem und Weltpatentsystem. In: GRUR Int. 39(9), S. 684–690 Open Google Scholar
  313. Vanderberg, J.P. (2009): Reflections on early malaria vaccine studies, the first suc-cessful human malaria vaccination, and beyond. In: Vaccine 27(1), S. 2–9 Open Google Scholar doi.org/10.1016/j.vaccine.2008.10.028
  314. Venhoff, A.C.; Lebrecht, D.; Reuss, F.U.; Heckl-Östreicher, B.; Wehr, R.; Walker, U.A.; Venhoff, N.. (2009): Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug. In: Antimicrobial Agents and Chemotherapy 53(7), S. 2748–2751 Open Google Scholar doi.org/10.1128/AAC.00364-09
  315. vfa (Verband Forschender Arzneimittelhersteller e.V.) (2005): Der Schutz des geisti-gen Eigentums. Patente – Voraussetzung für Innovation. Berlin Open Google Scholar
  316. vfa (2011): Gemeinsam für Gesundheit und Entwicklung – Patente fördern Entwick-lung. www.vfa.de/de/wirtschaft-politik/artikel-wirtschaft-politik/medikamente-in- Open Google Scholar
  317. entwicklungslaendern.html/_4-patente-foerdern-entwicklung (15.6.2015) Open Google Scholar
  318. vfa (2013): Forschung für das Leben. Entwicklungsprojekte für innovative Arznei-mittel. Berlin Open Google Scholar
  319. Wagner-Ahlfs, C. (2014a): Neue Sterne am Horizont: EU-Forschungsförderung. In: Pharma-Brief Nr. 5, S. 2–4 Open Google Scholar
  320. Wagner-Ahlfs, C. (2014b): WHO: Neue Wege in der Forschung. In: Pharma-Brief Nr. 5, S. 4–5 Open Google Scholar
  321. Wamser, J. (2005): Standort Indien. Der Subkontinentalstaat als Markt und Investiti-onsziel ausländischer Unternehmen. Bochum Open Google Scholar
  322. Wasunna, A.A. (2007): Brinkmanship and compulsory licensing – policy lessons from Brazil. In: International Journal of Biotechnology 9 (2), S. 105–121 Open Google Scholar doi.org/10.1504/IJBT.2007.013046
  323. WD (Wissenschaftliche Dienste) (2014): Die Auswirkungen von TTIP auf Entwick-lungs- und Schwellenländer. Der Schutz des geistigen Eigentums in bi- und mul-tilateralen Handelsabkommen und dessen Auswirkungen auf den Zugang zu Medikamenten durch die Entwicklungs- und Schwellenländer. Deutscher Bun-destag, WD 2 – 3000 – 094/14, Berlin Open Google Scholar
  324. Weltbank (1993): Weltentwicklungsbericht 1993. Investitionen in die Gesundheit. Washington (D.C.) Open Google Scholar
  325. WHA (World Health Assembly) (2008): Global strategy and plan of action on public health, innovation and intellectual property. (WHA61.21), http://apps.who.int/ Open Google Scholar
  326. gb/ebwha/pdf_files/A61/A61_R21-en.pdf (8.1.2014) Open Google Scholar
  327. White, K. (2006): Malaria – time to act. In: New England Journal of Medicine 355(19), S. 1956–1957 Open Google Scholar doi.org/10.1056/NEJMp068214
  328. White, M.T.; Conteh, L.; Cibulskis, R.; Ghani, A.C. (2011): Costs and cost-effectiveness of Malaria control interventions – a systematic review. In: Malaria Journal 10:337 Open Google Scholar doi.org/10.1186/1475-2875-10-337
  329. WHO (World Health Organisation) (1946): Constitution of the World Health Organ-ization. www.who.int/governance/eb/who_constitution_en.pdf, (deutsche Übersetzung: www.admin.ch/opc/de/classified-compilation/19460131/200906250000/0.810.1.pdf [8.1.2014]) Open Google Scholar
  330. WHO (1998): Report of the 2nd WHOPES working group meeting – review of al-pha-cypermethrin 10 %SC and 5 %WP and cyfluthrin 5 %EW and 10 %WP. http://whq Open Google Scholar
  331. libdoc.who.int/hq/1998/CTD_WHOPES_98.10.pdf?ua=1 (30.4.2015) Open Google Scholar
  332. WHO (2002): Report of the sixth WHOPES working group meeting. http://whqlibdoc. Open Google Scholar
  333. who.int/hq/2002/WHO_CDS_WHOPES_2002.6.pdf?ua=1 (9.3.2015) Open Google Scholar
  334. WHO (2003): The quality of antimalarials. A study in selected African countries. http://whqlibdoc.who.int/hq/2003/WHO_EDM_PAR_2003.4.pdf (9.3.2015) Open Google Scholar
  335. WHO (2006a): Global Malaria Programme, Indoor residual spraying. http://whqlib Open Google Scholar
  336. doc.who.int/hq/2006/WHO_HTM_MAL_2006.1112_eng.pdf (20.2.2015) Open Google Scholar
  337. WHO (2006b): Report of the 10th WHOPES Working Group meeting, http://whqlib Open Google Scholar
  338. doc.who.int/hq/2007/WHO_CDS_NTD_WHOPES_2007_1_eng.pdf?ua=1 (30.4.2015) Open Google Scholar
  339. WHO (2007): Global Malaria Programme, Insecticide-treated Mosquito Nets. www. Open Google Scholar
  340. who.int/malaria/publications/atoz/itnspospaperfinal.pdf (20.2.2015) Open Google Scholar
  341. WHO (2010a): Defining and validating a measure of parasite resistance to sulfadox-ine-pyrimethamine (SP) that would be indicative of the protective efficacy of SP for intermittent preventive treatment in infancy (IPTi-SP). www.who.int/entity/mala Open Google Scholar
  342. ria/publications/atoz/who_sp_ipti_resistance_march_2010.pdf?ua=1 (9.3.2015) Open Google Scholar
  343. WHO (2010b): Guidelines for the treatment of malaria. Second edition. http://whq Open Google Scholar
  344. libdoc.who.int/publications/2010/9789241547925_eng.pdf?ua=1 (9.3.2015) Open Google Scholar
  345. WHO (2012a): Accelerating work to overcome the global impact of neglected tropi-cal diseases – a roadmap for implementation. www.who.int/neglected_diseases/NTD_ Open Google Scholar
  346. RoadMap_2012_Fullversion.pdf (10.12.2014) Open Google Scholar
  347. WHO (2012b): Global strategy for Dengue prevention and control. http://apps.who. Open Google Scholar
  348. int/iris/bitstream/10665/75303/1/9789241504034_eng.pdf?ua=1 (10.12.2014) Open Google Scholar
  349. WHO (2012c): T3: Test. Treat. Track. Scaling up diagnostic testing, treatment and surveillance for malaria. www.who.int/malaria/publications/atoz/test_treat_track_bro Open Google Scholar
  350. chure.pdf?ua=1 (2.3.2015) Open Google Scholar
  351. WHO (2012d): Report of the 15th whopes working group meeting. http://apps.who. Open Google Scholar
  352. int/iris/bitstream/10665/75304/1/9789241504089_eng.pdf?ua=1 (30.4.2015) Open Google Scholar
  353. WHO (2013a): Sustaining the drive to overcome the global impact of neglected trop-ical diseases Second WHO report on neglected tropical diseases. www.who.int/iris/ Open Google Scholar
  354. bitstream/10665/77950/1/9789241564540_eng.pdf (20.4.2015) Open Google Scholar
  355. WHO (2013b): WHO model list of essential medicines. 18th list. www.who.int/medi Open Google Scholar
  356. cines/publications/essentialmedicines/18th_EML.pdf (10.11.2014) Open Google Scholar
  357. WHO (2013c): Prequalification of medicines by WHO. Fact sheet No. 278. www.who. Open Google Scholar
  358. int/mediacentre/factsheets/fs278/en/ (9.3.2015) Open Google Scholar
  359. WHO (2013d): WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). www.who.int/entity/malaria/publications/atoz/iptp-sp-updated-policy-brief-24jan Open Google Scholar
  360. 2014.pdf?ua=1 (9.3.2015) Open Google Scholar
  361. WHO (2013e): Report of the sixteenth WHOPES working group meeting. http://apps. Open Google Scholar
  362. who.int/iris/bitstream/10665/90976/1/9789241506304_eng.pdf?ua=1 (9.3.2015) Open Google Scholar
  363. WHO (2013f): The selection and use of essential medicines. http://apps.who.int/iris/ Open Google Scholar
  364. bitstream/10665/112729/1/WHO_TRS_985_eng.pdf?ua=1 (20.4.2015) Open Google Scholar
  365. WHO (2013g): Overview of the WHO pesticide evaluation scheme (WHOPES). http:// Open Google Scholar
  366. aplma.org/upload/resource/Papers/who%20pesticide%20evaluation%20scheme. Open Google Scholar
  367. pdf (20.4.2015) Open Google Scholar
  368. WHO (2014a): Global Tuberculosis report 2014. Genf Open Google Scholar
  369. WHO (2014b): World Malaria report 2014. http://apps.who.int/iris/bitstream/10665/ Open Google Scholar
  370. 144852/2/9789241564830_eng.pdf?ua=1&ua=1&ua=1 (20.2.2015) Open Google Scholar
  371. WHO (2014c): Global status report on noncommunicable diseases 2014. Genf Open Google Scholar
  372. WHO (2014d): Malaria rapid diagnostic test performance. http://apps.who.int/iris/ Open Google Scholar
  373. bitstream/10665/128678/1/9789241507554_eng.pdf?ua=1&ua=1 (12.3.2015) Open Google Scholar
  374. WHO; GFATM (2008): Guide to operarional research in programs. www.who.int/hiv/' Open Google Scholar
  375. pub/operational/or_guide_gf.pdf (15.3.2015) Open Google Scholar
  376. WHO; hai global (Health Action International) (2008): Measuring medicine prices, availability, affordability and price components. www.who.int/medicines/areas/ Open Google Scholar
  377. access/OMS_Medicine_prices.pdf (28.7.2015) Open Google Scholar
  378. Widmann-Mauz, A. (2013): Antwort der Parlamentarischen Staatssekretärin vom 28. Dezember 2012. In: Deutscher Bundestag, Drucksache Nr. 17/12008, S. 50 Open Google Scholar
  379. Widmann-Mauz, A. (2015): Antwort der Parlamentarischen Staatssekretärin vom 14. August 2015. In: Deutscher Bundestag, Drucksache Nr. 18/5768, S. 38 Open Google Scholar
  380. Williams, O. D. (2012): Access to medicines, market failure and market intervention: a tale of two regimes. In: Global Public Health 7(2), S. 127–143 Open Google Scholar doi.org/10.1080/17441692.2012.725753
  381. Wilson, P. (2010): Giving developing countries best shot: An overview of vaccines access and R&D. Hg.: Oxfam, MSF; www.oxfam.org/sites/www.oxfam.org/files/ Open Google Scholar
  382. giving-developing-countries-best-shot-vaccines-2010-05.pdf (10.10.2015) Open Google Scholar
  383. WIPO (World Intellectual Property Organization) (2011): Patent landscape report on Ritonavir. www.wipo.int/edocs/pubdocs/en/patents/946/wipo_pub_946.pdf Open Google Scholar
  384. (20.5.2015) Open Google Scholar
  385. Wogart, J.P.; Calcagnotto, G.; Hein, W.; von Soest, Ch. (2008): AIDS, access to medicines, and the different roles of the Brazilian and South African govern-ment in global health governance. GIGA Working Paper No. 86, Hamburg Open Google Scholar doi.org/10.2139/ssrn.1286066
  386. Wolf, R. (2015): Das Albert-Schweitzer-Spital in Lambarene: Fakten und Zahlen. www.albert-schweitzer-zentrum.de/uploads/media/Fakten_und_Zahlen_zum_ Open Google Scholar
  387. Albert-Schweitzer-Spital.pdf (20.10.2015) Open Google Scholar
  388. Woll, C.; Artigas, A. (2007): When trade liberalization turns into regulatory reform: The impact on business-government relations in international trade politics. In: Regulation and Governance 1(2), S. 121–138 Open Google Scholar doi.org/10.1111/j.1748-5991.2007.00010.x
  389. WTO (World Trade Organization) (2015): Extension of the transition period under Article 66.1 of the TRIPS-agreement for least developed country members for certain obligations with respect to pharmaceutical products. Decision of the Council for TRIPS of 6 November 2015. Decision Number IP/C/73, Genf Open Google Scholar
  390. Yu, P.K. (2004): Currents and crosscurrents in the international intellectual property regime. In: Loy. L.A.L.Rev. 38(323), S. 323–444 Open Google Scholar

Similar publications

from the topics "Cultural History & Cultural Studies", "Education General", "Environmental Economics & Environmental Management & Energy Economy", "Economics"
Cover of book: Gute Poesie
Book Titles No access
Christian Eger
Gute Poesie
Cover of book: Musical Traces of a Lost Past
Edited Book No access
Dilek Kızıldağ, Martin Greve
Musical Traces of a Lost Past
Cover of book: Comparative Perspectives on the Law of Energy Transition in Europe
Edited Book Full access
Michael Rodi, Johannes Saurer
Comparative Perspectives on the Law of Energy Transition in Europe
Cover of book: Lehren und Lernen von Bewegungen
Book Titles Full access
Jörg Bietz, Hans-Georg Scherer
Lehren und Lernen von Bewegungen
Cover of book: Kapital als Medium
Book Titles No access
Michael Mayer
Kapital als Medium

Notice

This work is protected by copyright and may only be used in accordance with the provisions of the Terms of Use and License Agreement. Any use of the work beyond this is expressly prohibited and will be prosecuted.

Give feedback

We welcome your feedback on content and features. Your message helps us to continuously improve our service.

Rating
Attach images
or drag and drop
PNG or JPG (max. 3 MB)

Login

Forgotten your password?
Login via Open Athens
Don't have an account yet?
Register now

Cite publication

Download: RIS BibTex